CorMedix (NASDAQ:CRMD) Shares Down 5.9% – What’s Next?

Posted by Stanley Muller on Jul 20th, 2026

CorMedix Inc (NASDAQ:CRMD – Get Free Report) shares fell 5.9% on Monday . The stock traded as low as $8.00 and last traded at $7.9250. Approximately 458,762 shares were traded during mid-day trading, a decline of 74% from the average session volume of 1,793,413 shares. The stock had previously closed at $8.42.

Analysts Set New Price Targets

Several equities analysts recently commented on CRMD shares. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of CorMedix in a research report on Monday, April 27th. Weiss Ratings upgraded CorMedix from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, May 14th. Needham & Company LLC lifted their price target on CorMedix from $14.00 to $15.00 and gave the stock a “buy” rating in a research note on Monday, April 27th. Royal Bank Of Canada cut their price objective on CorMedix from $14.00 to $13.00 and set an “outperform” rating for the company in a report on Tuesday, July 7th. Finally, Leerink Partners increased their price objective on CorMedix from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, April 28th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, CorMedix currently has a consensus rating of “Moderate Buy” and an average target price of $14.86.

Check Out Our Latest Report on CRMD

CorMedix Stock Performance

The company’s fifty day moving average is $8.32 and its 200 day moving average is $7.82. The company has a market cap of $621.72 million, a P/E ratio of 3.74 and a beta of 1.48. The company has a current ratio of 2.97, a quick ratio of 2.74 and a debt-to-equity ratio of 0.33.

CorMedix (NASDAQ:CRMD – Get Free Report) last announced its quarterly earnings data on Thursday, May 14th. The company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.35 by $0.08. The firm had revenue of $127.43 million during the quarter, compared to the consensus estimate of $104.96 million. CorMedix had a return on equity of 45.57% and a net margin of 45.25%.The business’s revenue was up 226.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.30 earnings per share. As a group, equities analysts predict that CorMedix Inc will post 0.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Deerfield Management Company L.P. bought a new position in shares of CorMedix during the third quarter valued at $38,656,000. Marshall Wace LLP boosted its stake in CorMedix by 34.6% in the 3rd quarter. Marshall Wace LLP now owns 3,473,494 shares of the company’s stock worth $40,397,000 after purchasing an additional 893,518 shares in the last quarter. UBS Group AG boosted its stake in CorMedix by 295.3% in the 3rd quarter. UBS Group AG now owns 1,090,908 shares of the company’s stock worth $12,687,000 after purchasing an additional 814,964 shares in the last quarter. Jump Financial LLC purchased a new stake in CorMedix during the 3rd quarter valued at about $9,003,000. Finally, Goldman Sachs Group Inc. grew its position in CorMedix by 259.1% during the 4th quarter. Goldman Sachs Group Inc. now owns 828,781 shares of the company’s stock valued at $9,639,000 after purchasing an additional 597,971 shares during the last quarter. 34.18% of the stock is currently owned by institutional investors.

CorMedix Company Profile

(Get Free Report)

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company’s lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.